Key takeaways
- 40-60% Estimated NPHC individual-application approval rate for switching LOPD patients from alglucosidase to avalglucosidase
- SAR 100-160M Estimated annual NPHC Pompe ERT budget across 80-120 patients
- SAR 30-60K Annual per-patient infusion logistics cost, separate from drug cost — the basis for the home-infusion commercial case
NPHC's Pompe coverage is well-established for both IOPD and LOPD, but avalglucosidase access still runs through a documented-failure switch criterion Sanofi is working to bypass.
NPHC's Pompe ERT programme is comprehensive. Infantile-onset Pompe disease (IOPD), confirmed via GAA enzyme activity below 1% and identified through newborn screening or symptomatically, receives immediate ERT initiation at an NPHC-designated centre. Late-onset Pompe disease (LOPD) requires confirmed GAA enzyme activity and mutation plus either FVC below 70% or a documented 6-minute walk test decline of at least 10% over 12 months, with ERT initiation following specialist NPHC committee review. Continuation requires FVC/6MWT reassessment at 12 months. The annual NPHC Pompe ERT budget is estimated at SAR 100-160 million, covering 80-120 patients at an average SAR 1-1.5 million per year, with alglucosidase alfa (Lumizyme) as the dominant, formulary-covered ERT — annual cost SAR 800,000-1,200,000 depending on patient weight at the standard 20 mg/kg biweekly dose.
Avalglucosidase alfa (Nexviazyme), SFDA-registered in 2022, has not yet established NPHC switch criteria for existing alglucosidase patients; Sanofi is instead pursuing NPHC first-line approval to bypass the switch requirement entirely for new LOPD patients. In the interim, individual case submission is available for LOPD patients switching from alglucosidase, requiring 12 or more months of alglucosidase therapy with documented FVC decline of at least 5% or 6MWT decline of at least 10%, anti-drug antibody (CRIM status) assessment, and specialist metabolic physician endorsement, with an estimated approval rate of 40-60%. Annual avalglucosidase cost in the GCC is estimated at SAR 1,200,000-1,800,000, a premium over alglucosidase. Beyond the drug itself, biweekly infusion logistics (nursing, supplies) cost SAR 30,000-60,000 per patient per year; KFSH&RC piloted home infusion for stable LOPD patients in 2022, and Sanofi's GCC Patient Support Programme now covers nurse home visits at five GCC centres — both a commercial differentiator for Sanofi and a budget-efficiency argument NPHC is likely to find persuasive.
GCC Pompe disease agent access status — 2026
| Drug (Brand / INN) | SFDA / GCC Registration Status | NPHC / MOH Coverage Pathway | GCC Pricing | Key Access Barrier |
|---|---|---|---|---|
| Lumizyme (alglucosidase alfa) | SFDA registered; NPHC listed | NPHC covers both IOPD and LOPD (GAA activity + clinical criteria) | SAR 800,000-1,200,000/year | Dominant ERT; 12-month continuation review required |
| Nexviazyme (avalglucosidase alfa) | SFDA 2022; NPHC evaluation ongoing | Individual case submission for switch; no routine formulary yet | SAR 1,200,000-1,800,000/year | Switch approval only 40-60%; Sanofi pursuing NPHC first-line bypass |
Sources: NPHC Pompe disease programme guidelines 2023; GCC metabolic network registry; NPHC Pompe programme committee review process 2023; Sanofi GCC rare disease team; KFSH&RC home infusion pilot data 2022; Sanofi GCC PSP documentation.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- What are NPHC's exact IOPD and LOPD coverage criteria, and how does the 12-month continuation review work? • Full NPHC Pompe coverage criteria by IOPD/LOPD • continuation FVC/6MWT reassessment protocol • NPHC Pompe budget documentation (SAR 100-160M)
- What does the avalglucosidase individual-switch application require, and why is Sanofi pursuing NPHC first-line approval instead? • Avalglucosidase switch-criteria detail (12-month failure documentation, CRIM status, specialist endorsement) • first-line-approval strategy analysis and evidence requirements
- How does the home-infusion programme change the commercial and NPHC-budget case for Pompe ERT, and what is the GCC rollout status? • KFSH&RC home-infusion pilot data and Sanofi PSP GCC centre coverage • budget-efficiency argument quantification for NPHC engagement
What's inside
-
1 · NPHC Pompe Programme — IOPD and LOPD Coverage Criteria 5 pp
- Why IOPD triggers immediate ERT at GAA enzyme activity below 1%, while LOPD requires FVC under 70% or a 10% 6MWT decline before committee review
- How the 12-month continuation review re-tests FVC and 6-minute walk test results to justify ongoing NPHC funding for each patient
-
2 · NPHC Budget Exposure and 12-Month Continuation Review 4 pp
- Why the SAR 100-160 million annual NPHC Pompe budget across 80-120 patients averages SAR 1-1.5 million per patient per year
- How Lumizyme's SAR 800,000-1,200,000 annual cost at the standard 20 mg/kg biweekly dose varies with patient weight
-
3 · Avalglucosidase Switch Criteria — Individual Case Submission 5 pp
- Why switching from alglucosidase requires 12+ months of documented therapy plus a 5% FVC or 10% 6MWT decline before submission
- Why only 40-60% of individual switch applications are approved despite CRIM status assessment and specialist endorsement
-
4 · Sanofi's NPHC First-Line Approval Strategy 3 pp
- Why Sanofi is pursuing first-line NPHC approval for new LOPD patients rather than relying on the individual-switch pathway
- What bypassing the switch-criteria requirement would mean for avalglucosidase's share of new Pompe starts under NPHC
-
5 · GCC Pompe ERT Pricing — Alglucosidase vs Avalglucosidase 4 pp
- Why avalglucosidase's SAR 1.2-1.8 million annual cost carries a premium over alglucosidase's SAR 800,000-1,200,000
- How biweekly infusion logistics add SAR 30,000-60,000 per patient annually on top of either ERT's drug cost
-
6 · Home Infusion — Commercial Differentiator and Budget Case 4 pp
- How KFSH&RC's 2022 home-infusion pilot for stable LOPD patients is being scaled through Sanofi's Patient Support Programme
- Why nurse home visits at five GCC centres double as a commercial differentiator and an NPHC budget-efficiency argument
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx Pompe Disease Payer & HTA (GCC) is built for market access and pricing teams navigating NPHC's IOPD/LOPD coverage criteria, the avalglucosidase switch-access bar, and the home-infusion commercial case across Saudi Arabia and the GCC metabolic disease network. Custom assessment in 72 hours.
- 1. Submit your requestSpecify indication, GCC payer focus (NPHC criteria, switch-access strategy), and commercial question.
- 2. Scoping callAXLRx analyst confirms GCC market scope (KSA-first or pan-GCC), NPHC coverage analysis, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment is built from NPHC Pompe disease programme guidelines, the GCC metabolic network registry, and Sanofi's GCC rare disease team documentation.
Key sources: NPHC Pompe disease programme guidelines (2023); GCC metabolic network registry; NPHC Pompe programme committee review process documentation (2023); Sanofi GCC rare disease team data; KFSH&RC home infusion pilot data (2022); Sanofi GCC Patient Support Programme documentation.
- NPHC IOPD/LOPD coverage criteria verified against NPHC Pompe disease programme guidelines (2023)
- Avalglucosidase switch criteria and approval rate verified against NPHC Pompe programme committee review process documentation (2023)
- GCC pricing verified against Sanofi GCC rare disease team data
- Home infusion programme details verified against KFSH&RC home infusion pilot data (2022) and Sanofi GCC PSP documentation
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model (NPHC/MOH coverage grid or drug comparison data, depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: NPHC Pompe programme guidelines and committee review documentation, the regional metabolic-network registry, named-centre home-infusion pilot data, and manufacturer patient-support programme records. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered assessment.
Customisation Can I tailor the assessment to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target GCC market (KSA, UAE, Qatar, Kuwait, Oman, Bahrain), key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions, such as additional GCC state deep-dives, pipeline agent profiles, or private-insurer coverage analysis, can be added to any standard assessment. Commission via the intake form to start.